

Parkinson's disease-linked LRRK2 is expressed in circ
upregulated following recognition of microbial structure

Journal of Neural Transmission

118, 795-808

DOI: [10.1007/s00702-011-0653-2](https://doi.org/10.1007/s00702-011-0653-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions?. Biochemical Society Transactions, 2012, 40, 1095-1101.	1.6	20
2	LRRK2 Inhibition Attenuates Microglial Inflammatory Responses. Journal of Neuroscience, 2012, 32, 1602-1611.	1.7	386
3	The role of LRRK2 in inflammatory bowel disease. Cell Research, 2012, 22, 1092-1094.	5.7	42
4	G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Human Molecular Genetics, 2012, 21, 4201-4213.	1.4	147
5	Programmed Cell Death in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009365-a009365.	2.9	196
6	Inflammation in Parkinson's Disease. Advances in Protein Chemistry and Structural Biology, 2012, 88, 69-132.	1.0	154
7	The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. Journal of Neuroinflammation, 2012, 9, 66.	3.1	57
8	LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. Journal of Neuroinflammation, 2012, 9, 261.	3.1	77
9	Parkinson's disease and immune system: is the culprit LRRK2 in the periphery?. Journal of Neuroinflammation, 2012, 9, 94.	3.1	34
10	Cellular effects of LRRK2 mutations. Biochemical Society Transactions, 2012, 40, 1070-1073.	1.6	20
11	A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling. Biochemical Society Transactions, 2012, 40, 1140-1146.	1.6	26
12	Evolution of Neurodegeneration. Current Biology, 2012, 22, R753-R761.	1.8	18
13	Inflammation and neurodegeneration: the story "retold". Trends in Pharmacological Sciences, 2012, 33, 542-551.	4.0	57
14	An emerging role for LRRK2 in the immune system. Biochemical Society Transactions, 2012, 40, 1134-1139.	1.6	36
15	Viral and Inflammatory Triggers of Neurodegenerative Diseases. Science Translational Medicine, 2012, 4, 121ps3.	5.8	77
16	A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease. Parkinson's Disease, 2012, 2012, 1-9.	0.6	21
17	The Role of Autophagy in Crohn's Disease. Cells, 2012, 1, 492-519.	1.8	26
18	Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson Disease. Current Treatment Options in Neurology, 2012, 14, 230-240.	0.7	21

#	ARTICLE	IF	CITATIONS
19	Digesting the genetics of inflammatory bowel disease: Insights from studies of autophagy risk genes. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 782-792.	0.9	38
20	Neuroinflammation and Non-motor Symptoms: The Dark Passenger of Parkinson's Disease?. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 350-358.	2.0	68
21	The role of α -synuclein in neurodegeneration – An update. <i>Translational Neuroscience</i> , 2012, 3, .	0.7	16
22	Inhibition of LRRK2 kinase activity stimulates macroautophagy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 2900-2910.	1.9	124
23	Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. <i>Experimental Neurology</i> , 2013, 241, 148-155.	2.0	34
24	Unlocking the secrets of LRRK2 function with selective kinase inhibitors. <i>Future Neurology</i> , 2013, 8, 347-357.	0.9	4
25	The role of inflammation in sporadic and familial Parkinson's disease. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 4259-4273.	2.4	153
26	The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: Clinical and demographic characteristics. <i>Neuroscience Letters</i> , 2013, 537, 1-5.	1.0	41
27	Acute spinal cord injury could cause activation of autophagy in dorsal root ganglia. <i>Spinal Cord</i> , 2013, 51, 679-682.	0.9	17
28	LRRK2: Cause, Risk, and Mechanism. <i>Journal of Parkinson's Disease</i> , 2013, 3, 85-103.	1.5	128
30	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2013, 3, 145-152.	1.5	44
31	The Role of Innate and Adaptive Immunity in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 493-514.	1.5	249
32	LRRK2 and RIPK2 Variants in the NOD 2-Mediated Signaling Pathway Are Associated with Susceptibility to <i>Mycobacterium leprae</i> in Indian Populations. <i>PLoS ONE</i> , 2013, 8, e73103.	1.1	45
33	LRRK-2 as a Key Molecule Bridging Inflammation to Parkinson's Disease. <i>Advances in Neuroimmune Biology</i> , 2013, 4, 205-215.	0.7	0
34	Surfactant Secretion in LRRK2 Knock-Out Rats: Changes in Lamellar Body Morphology and Rate of Exocytosis. <i>PLoS ONE</i> , 2014, 9, e84926.	1.1	42
35	Original article Low prevalence of most frequent pathogenic variants of six PARK genes in sporadic Parkinson's disease. <i>Folia Neuropathologica</i> , 2014, 1, 22-29.	0.5	12
36	The Potential of Targeting LRRK2 in Parkinson's Disease. , 2014, , .		0
37	Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. <i>Human Molecular Genetics</i> , 2014, 23, 6212-6222.	1.4	66

#	ARTICLE	IF	CITATIONS
38	Unique Functional and Structural Properties of the LRRK2 Protein ATP-binding Pocket. <i>Journal of Biological Chemistry</i> , 2014, 289, 32937-32951.	1.6	26
39	Modeling LRRK2 Pathobiology in Parkinson's Disease: From Yeast to Rodents. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 22, 331-368.	0.8	18
40	LRRK2: dropping (kinase) inhibitions and seeking an (immune) response. <i>Journal of Neurochemistry</i> , 2014, 129, 895-897.	2.1	4
41	Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2. <i>Glia</i> , 2014, 62, 1075-1092.	2.5	15
42	Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. <i>Movement Disorders</i> , 2014, 29, 991-998.	2.2	107
43	The role of the LRRK2 gene in Parkinsonism. <i>Molecular Neurodegeneration</i> , 2014, 9, 47.	4.4	180
44	LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?. <i>Journal of Neuroinflammation</i> , 2014, 11, 52.	3.1	148
45	Hypothesis: A role for EBV-induced molecular mimicry in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 685-694.	1.1	52
46	Molecular basis of Parkinson's disease linked to LRRK2 mutations. <i>Molecular Biology</i> , 2014, 48, 1-10.	0.4	9
47	Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. <i>Human Molecular Genetics</i> , 2014, 23, 4201-4214.	1.4	197
48	Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation. <i>Journal of Neuroscience Research</i> , 2014, 92, 506-516.	1.3	21
49	Interferon- γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages. <i>Journal of Neurochemistry</i> , 2014, 129, 980-987.	2.1	58
50	Genetic, Structural, and Molecular Insights into the Function of Ras of Complex Proteins Domains. <i>Chemistry and Biology</i> , 2014, 21, 809-818.	6.2	20
51	Peptidoglycan recognition protein genes and risk of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1171-1180.	2.2	47
52	Microglia in Health and Disease. , 2014, , .		19
54	Primary Effusion Lymphoma. <i>American Journal of Pathology</i> , 2014, 184, 618-630.	1.9	14
55	LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis. <i>Experimental Neurology</i> , 2014, 261, 206-216.	2.0	82
56	The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson's Disease. <i>Neurochemical Research</i> , 2014, 39, 576-592.	1.6	61

#	ARTICLE	IF	CITATIONS
57	Cellular processes associated with <sc>LRRK</sc>2 function and dysfunction. FEBS Journal, 2015, 282, 2806-2826.	2.2	144
58	Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF- κ B p50 signaling in cultured microglia cells. Journal of Neuroinflammation, 2015, 12, 230.	3.1	99
59	Neuroinflammation in Parkinsonâ€™s disease and its potential as therapeutic target. Translational Neurodegeneration, 2015, 4, 19.	3.6	608
60	Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond. BMB Reports, 2015, 48, 243-248.	1.1	36
61	Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. Current Topics in Behavioral Neurosciences, 2015, , .	0.8	13
62	Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy, 2015, 11, 1443-1457.	4.3	217
63	New insights on Parkinsonâ€™s disease genes: the link between mitochondria impairment and neuroinflammation. Journal of Neural Transmission, 2015, 122, 1409-1419.	1.4	24
64	Leucineâ€™rich repeat kinase 2â€™sensitive Na + /Ca 2+ exchanger activity in dendritic cells. FASEB Journal, 2015, 29, 1701-1710.	0.2	16
65	The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Human Molecular Genetics, 2015, 24, 4250-4267.	1.4	58
66	TCF-1 and LEF-1 help launch the TFH program. Nature Immunology, 2015, 16, 900-901.	7.0	8
67	LRRK2 and Nod2 promote lysozyme sorting in Paneth cells. Nature Immunology, 2015, 16, 898-900.	7.0	26
68	Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair. International Journal of Neuroscience, 2015, 125, 717-725.	0.8	138
69	Inflammation is genetically implicated in Parkinsonâ€™s disease. Neuroscience, 2015, 302, 89-102.	1.1	182
70	The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinsonâ€™s disease. Neuroscience, 2015, 302, 74-88.	1.1	110
71	The Role of LRRK2 in the Regulation of Monocyte Adhesion to Endothelial Cells. Journal of Molecular Neuroscience, 2015, 55, 233-239.	1.1	22
72	Inflammatory profile in LRRK2-associated prodromal and clinical PD. Journal of Neuroinflammation, 2016, 13, 122.	3.1	57
73	Inhibitor treatment of peripheral mononuclear cells from Parkinsonâ€™s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports, 2016, 6, 31391.	1.6	32
74	Leucine-rich repeat kinase 2 (LRRK2) regulates α -synuclein clearance in microglia. BMC Neuroscience, 2016, 17, 77.	0.8	48

#	ARTICLE	IF	CITATIONS
75	LRRK2 contributes to monocyte dysregulation in Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2016, 4, 123.	2.4	29
76	Association Between Parkinson's Disease and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1049-1055.	0.9	154
77	The role of autophagy in modulation of neuroinflammation in microglia. <i>Neuroscience</i> , 2016, 319, 155-167.	1.1	148
78	Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. <i>European Journal of Neurology</i> , 2017, 24, 427.	1.7	56
79	LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. <i>Biochemical Society Transactions</i> , 2017, 45, 131-139.	1.6	72
80	LRRK2: An Emerging New Molecule in the Enteric Neuronal System That Quantitatively Regulates Neuronal Peptides and IgA in the Gut. <i>Digestive Diseases and Sciences</i> , 2017, 62, 903-912.	1.1	17
81	Leucine-Rich Repeat Kinase 2 (Lrrk2)-Sensitive Na ⁺ /K ⁺ ATPase Activity in Dendritic Cells. <i>Scientific Reports</i> , 2017, 7, 41117.	1.6	5
82	LRRK2 levels in immune cells are increased in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2017, 3, 11.	2.5	177
83	Holocranohistochemistry enables the visualization of Î±-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. <i>Journal of Neural Transmission</i> , 2017, 124, 721-738.	1.4	42
84	LRRK2 and the Immune System. <i>Advances in Neurobiology</i> , 2017, 14, 123-143.	1.3	42
85	LRRK2 Phosphorylation. <i>Advances in Neurobiology</i> , 2017, 14, 51-70.	1.3	16
87	LRRK2. , 2017, , 107-116.		1
88	Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. <i>Progress in Medicinal Chemistry</i> , 2017, 56, 37-80.	4.1	17
89	Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. <i>Scientific Reports</i> , 2017, 7, 10300.	1.6	88
90	Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1093-1102.	1.5	28
91	Leucine-rich repeat kinase 2 and Parkinson's disease. <i>Proteomics</i> , 2017, 17, 1600092.	1.3	22
92	Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the R-EDIGT score. <i>European Journal of Neuroscience</i> , 2017, 45, 175-191.	1.2	17
93	Neuroinflammation as a Potential Mechanism Underlying Parkinsons Disease. , 2017, , 245-279.		4

#	ARTICLE	IF	CITATIONS
94	Discovering New Benefits From Old Drugs With Big Dataâ€™ Promise for Parkinson Disease. <i>JAMA Neurology</i> , 2018, 75, 917.	4.5	5
95	Role of LRRK2 in manganese-induced neuroinflammation and microglial autophagy. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 171-177.	1.0	50
96	LRRK2 Phosphorylation: Behind the Scenes. <i>Neuroscientist</i> , 2018, 24, 486-500.	2.6	17
97	Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. <i>Brain</i> , 2018, 141, 1753-1769.	3.7	106
98	Differential contribution of microglia and monocytes in neurodegenerative diseases. <i>Journal of Neural Transmission</i> , 2018, 125, 809-826.	1.4	84
99	The impact of murine LRRK2 G2019S transgene overexpression on acute responses to inflammatory challenge. <i>Brain, Behavior, and Immunity</i> , 2018, 67, 246-256.	2.0	14
100	Immune system responses in Parkinson's disease: Early and dynamic. <i>European Journal of Neuroscience</i> , 2019, 49, 364-383.	1.2	104
101	Brain injury induces HIF-1Î±-dependent transcriptional activation of LRRK2 that exacerbates brain damage. <i>Cell Death and Disease</i> , 2018, 9, 1125.	2.7	39
102	LRRK2 is a negative regulator of <i>Mycobacterium tuberculosis</i> phagosome maturation in macrophages. <i>EMBO Journal</i> , 2018, 37, .	3.5	140
103	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinsonâ€™s disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5164-E5173.	3.3	83
104	LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinsonâ€™s disease: a review. <i>Journal of Biomedical Science</i> , 2018, 25, 52.	2.6	29
105	Leucine-Rich Repeat Kinase 2 Controls the Ca ²⁺ /Nuclear Factor of Activated T Cells/IL-2 Pathway during Aspergillus Non-Canonical Autophagy in Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 210.	2.2	16
106	The kinase LRRK2 is differently expressed in chronic rhinosinusitis with and without nasal polyps. <i>Clinical and Translational Allergy</i> , 2018, 8, 8.	1.4	13
107	A role for viral infections in Parkinsonâ€™s etiology?. <i>Neuronal Signaling</i> , 2018, 2, NS20170166.	1.7	37
108	An increase in LRRK2 suppresses autophagy and enhances Dectin-1â€™-induced immunity in a mouse model of colitis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	98
109	Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinsonâ€™s disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 153.	3.1	76
110	Inflammatory Bowel Diseases and Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, S331-S344.	1.5	81
111	Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-BehÃ§et's Disease. <i>In Vivo</i> , 2019, 33, 1493-1497.	0.6	8

#	ARTICLE	IF	CITATIONS
112	<i>Lrrk2</i> alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	67
113	Are we listening to everything the PARK genes are telling us?. <i>Journal of Comparative Neurology</i> , 2019, 527, 1527-1540.	0.9	13
114	Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses. <i>Scientific Reports</i> , 2019, 9, 8795.	1.6	29
115	Î±-Synuclein pathology in Parkinson's disease and related Î±-synucleinopathies. <i>Neuroscience Letters</i> , 2019, 709, 134316.	1.0	177
116	A secret that underlies Parkinson's disease: The damaging cycle. <i>Neurochemistry International</i> , 2019, 129, 104484.	1.9	21
117	Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease. <i>Drugs</i> , 2019, 79, 1037-1051.	4.9	48
118	Leucine-rich repeat kinase 2 regulates mouse dendritic cell migration by ORAI2. <i>FASEB Journal</i> , 2019, 33, 9775-9784.	0.2	12
119	Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 374-382.	1.2	20
120	LRRK2 links genetic and sporadic Parkinson's disease. <i>Biochemical Society Transactions</i> , 2019, 47, 651-661.	1.6	148
121	The Parkinson's disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4. <i>Scientific Reports</i> , 2019, 9, 4515.	1.6	22
122	Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?. <i>Frontiers in Neurology</i> , 2019, 10, 232.	1.1	48
123	Roco Proteins: GTPases with a Baroque Structure and Mechanism. <i>International Journal of Molecular Sciences</i> , 2019, 20, 147.	1.8	31
124	Geochemical Characteristics of Oil from Oligocene Lower Ganchaigou Formation Oil Sand in Northern Qaidam Basin, China. <i>Natural Resources Research</i> , 2019, 28, 1521-1546.	2.2	1
125	Autophagy and LRRK2 in the Aging Brain. <i>Frontiers in Neuroscience</i> , 2019, 13, 1352.	1.4	44
126	Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons. <i>Journal of Parkinson's Disease</i> , 2019, 9, 121-139.	1.5	17
127	Dielectrophoretic characterization and separation of monocytes and macrophages using 3D carbon electrodes. <i>Electrophoresis</i> , 2019, 40, 315-321.	1.3	22
128	The key role of T cells in Parkinson's disease pathogenesis and therapy. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 25-31.	1.1	32
129	The unlikely partnership between <i>LRRK2</i> and Î±-synuclein in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2019, 49, 339-363.	1.2	35

#	ARTICLE	IF	CITATIONS
130	Joint-Connectivity-Based Sparse Canonical Correlation Analysis of Imaging Genetics for Detecting Biomarkers of Parkinson's Disease. <i>IEEE Transactions on Medical Imaging</i> , 2020, 39, 23-34.	5.4	39
131	Innate and adaptive immune responses in Parkinson's disease. <i>Progress in Brain Research</i> , 2020, 252, 169-216.	0.9	64
132	If <i>LRRK2</i> Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?. <i>Movement Disorders</i> , 2020, 35, 1727-1730.	2.2	4
133	Roles of lysosomotropic agents on <i>LRRK2</i> activation and Rab10 phosphorylation. <i>Neurobiology of Disease</i> , 2020, 145, 105081.	2.1	49
134	Interferon- β signaling synergizes with <i>LRRK2</i> in neurons and microglia derived from human induced pluripotent stem cells. <i>Nature Communications</i> , 2020, 11, 5163.	5.8	60
135	Nonsteroidal Anti-inflammatory Use and <i>LRRK2</i> Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.	2.2	57
136	Profiling Non-motor Symptoms in Monogenic Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 591183.	1.7	13
137	Oral <i>P. gingivalis</i> impairs gut permeability and mediates immune responses associated with neurodegeneration in <i>LRRK2</i> R1441G mice. <i>Journal of Neuroinflammation</i> , 2020, 17, 347.	3.1	41
138	Comprehensive Genomic Analysis Reveals the Prognostic Role of <i>LRRK2</i> Copy-Number Variations in Human Malignancies. <i>Genes</i> , 2020, 11, 846.	1.0	3
139	Pharmacodynamic Biomarkers for Emerging <i>LRRK2</i> Therapeutics. <i>Frontiers in Neuroscience</i> , 2020, 14, 807.	1.4	17
140	Exosome markers of <i>LRRK2</i> kinase inhibition. <i>Npj Parkinson's Disease</i> , 2020, 6, 32.	2.5	15
141	<i>LRRK2</i> Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages. <i>Stem Cell Reports</i> , 2020, 14, 940-955.	2.3	65
142	Multiple-Hit Hypothesis in Parkinson's Disease: <i>LRRK2</i> and Inflammation. <i>Frontiers in Neuroscience</i> , 2020, 14, 376.	1.4	43
143	Microglia depletion prior to lipopolysaccharide and paraquat treatment differentially modulates behavioral and neuronal outcomes in wild type and G2019S <i>LRRK2</i> knock-in mice. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 5, 100079.	1.3	9
144	Quantitative Measurements of <i>LRRK2</i> in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients. <i>Frontiers in Neuroscience</i> , 2020, 14, 526.	1.4	19
145	Crohn's and Parkinson's Disease-Associated <i>LRRK2</i> Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo. <i>Journal of Neuroimmune Pharmacology</i> , 2020, 15, 794-800.	2.1	15
146	Leucine-rich repeat kinase-2 (<i>LRRK2</i>) modulates microglial phenotype and dopaminergic neurodegeneration. <i>Neurobiology of Aging</i> , 2020, 91, 45-55.	1.5	33
147	Leucine Rich Repeat Kinase 2 and Innate Immunity. <i>Frontiers in Neuroscience</i> , 2020, 14, 193.	1.4	36

#	ARTICLE	IF	CITATIONS
148	Leucine-Rich Repeat Kinase 2 Controls Inflammatory Cytokines Production through NF- κ B Phosphorylation and Antigen Presentation in Bone Marrow-Derived Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1890.	1.8	7
149	The gut microbiome in Parkinson's disease: A culprit or a bystander?. <i>Progress in Brain Research</i> , 2020, 252, 357-450.	0.9	70
150	Neuroprotection by the Immunomodulatory Drug Pomalidomide in the <i>Drosophila</i> LRRK2WD40 Genetic Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 31.	1.7	13
151	Lysosome and Inflammatory Defects in <i>GBA1</i> Mutant Astrocytes Are Normalized by LRRK2 Inhibition. <i>Movement Disorders</i> , 2020, 35, 760-773.	2.2	79
152	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 275-286.	2.4	29
153	<i>SARS-CoV-2</i> : At the Crossroad Between Aging and Neurodegeneration. <i>Movement Disorders</i> , 2020, 35, 716-720.	2.2	114
154	Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. <i>Movement Disorders</i> , 2021, 36, 25-36.	2.2	69
155	Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?. <i>Npj Parkinson's Disease</i> , 2021, 7, 26.	2.5	46
156	The Contribution of Microglia to Neuroinflammation in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4676.	1.8	114
157	miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 661461.	1.8	18
158	Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. <i>Frontiers in Neurology</i> , 2021, 12, 681369.	1.1	10
159	Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells. <i>Neurochemistry International</i> , 2021, 147, 105070.	1.9	18
160	LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease. <i>Biomolecules</i> , 2021, 11, 1101.	1.8	19
161	Age-related LRRK2 G2019S Mutation Impacts Microglial Dopaminergic Fiber Refinement and Synaptic Pruning Involved in Abnormal Behaviors. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 527-543.	1.1	5
162	Modelling the functional genomics of Parkinson's disease in <i>Caenorhabditis elegans</i> : LRRK2 and beyond. <i>Bioscience Reports</i> , 2021, 41, .	1.1	8
163	Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort. <i>Frontiers in Neuroscience</i> , 2021, 15, 634666.	1.4	3
164	Neuroinflammation and Parkinson's Disease. , 2014, , 885-912.		1
165	Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology. <i>Scientific Reports</i> , 2016, 6, 30509.	1.6	53

#	ARTICLE	IF	CITATIONS
166	LRRK2 regulation of immune-pathways and inflammatory disease. <i>Biochemical Society Transactions</i> , 2019, 47, 1581-1595.	1.6	97
171	The IkappaB Kinase Family Phosphorylates the Parkinson's Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling. <i>PLoS ONE</i> , 2012, 7, e39132.	1.1	183
172	Leucine-Rich Î±2-Glycoprotein Is a Novel Biomarker of Neurodegenerative Disease in Human Cerebrospinal Fluid and Causes Neurodegeneration in Mouse Cerebral Cortex. <i>PLoS ONE</i> , 2013, 8, e74453.	1.1	49
173	Leucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response. <i>PLoS ONE</i> , 2015, 10, e0128906.	1.1	20
174	Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells. <i>PLoS ONE</i> , 2016, 11, e0165949.	1.1	18
175	Immunogenetics of Parkinson's Disease. , 0, , 27-44.		3
176	The Role of LRRK2 in Neurodegeneration of Parkinson Disease. <i>Current Neuropharmacology</i> , 2018, 16, 1348-1357.	1.4	95
177	LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's. <i>Frontiers in Neuroscience</i> , 2020, 14, 443.	1.4	47
178	HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice. <i>Experimental Neurobiology</i> , 2019, 28, 504-515.	0.7	31
179	Role of the Innate and Adaptive Immune System in the Pathogenesis of PD. , 2014, , 75-103.		14
181	Changes in the Immune System in Parkinson's Disease. , 2018, , 1-21.		0
182	Changes in the Immune System in Parkinson's Disease. , 2019, , 2353-2373.		0
185	Analysis of a precision medicine approach to treating Parkinson's disease: Analysis of the DATATOP study. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 15-21.	1.1	3
186	High-Throughput Sequencing Haplotype Analysis Indicates in LRRK2 Gene a Potential Risk Factor for Endemic Parkinsonism in Southeastern Moravia, Czech Republic. <i>Life</i> , 2022, 12, 121.	1.1	1
188	Infectious Agents as Potential Drivers of Î±-Synucleinopathies. <i>Movement Disorders</i> , 2022, 37, 464-477.	2.2	7
189	Significant modulations of linc001128 and linc0938 with miR-24-3p and miR-30c-5p in Parkinson disease. <i>Scientific Reports</i> , 2022, 12, 2569.	1.6	12
190	Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 24.	2.5	14
191	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. <i>Npj Parkinson's Disease</i> , 2022, 8, 34.	2.5	18

#	ARTICLE	IF	CITATIONS
192	Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 838-856.	2.9	25
193	LRRK2 as a target for modulating immune system responses. <i>Neurobiology of Disease</i> , 2022, 169, 105724.	2.1	11
197	The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	6
198	Therapeutic potential of leucine-rich repeat kinase 2 inhibitors for Parkinson's disease treatment. , 2022, , 623-655.		0
199	Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies. <i>Journal of Parkinson's Disease</i> , 2022, 12, S149-S163.	1.5	15
200	WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	13
201	The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. <i>Neurobiology of Disease</i> , 2022, 172, 105806.	2.1	7
202	G2019S LRRK2 Mutation Enhances MPP+-Induced Inflammation of Human Induced Pluripotent Stem Cells-Differentiated Dopaminergic Neurons. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	1
203	Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. <i>Genes</i> , 2022, 13, 1426.	1.0	4
204	Autophagic response to exercise in peripheral blood mononuclear cells from young men is intensity-dependent and is altered by exposure to environmental heat. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2022, 323, R467-R482.	0.9	4
207	Unraveling Parkinson's Disease Neurodegeneration: Does Aging Hold the Clues?. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2321-2338.	1.5	9
208	<sc>LRRK2</sc> expression in normal and pathologic human gut and in rodent enteric neural cell lines. <i>Journal of Neurochemistry</i> , 2023, 164, 193-209.	2.1	7
209	LRRK2 protects immune cells against erastin-induced ferroptosis. <i>Neurobiology of Disease</i> , 2022, 175, 105917.	2.1	12
211	Characterization of Lipopolysaccharide Effects on LRRK2 Signaling in RAW Macrophages. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1644.	1.8	3
212	Electroacupuncture alleviates neuropathic pain caused by spared nerve injury by promoting AMPK/mTOR-mediated autophagy in dorsal root ganglion macrophage. <i>Annals of Translational Medicine</i> , 2022, 10, 1341-1341.	0.7	3
213	The interplay between monocytes, α -synuclein and LRRK2 in Parkinson's disease. <i>Biochemical Society Transactions</i> , 2023, 51, 747-758.	1.6	1
214	<sc>LRRK2</sc> and Parkinson's disease: from genetics to targeted therapy. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 850-864.	1.7	5
218	Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	5

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------